Trending News

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

Supreme Court Eliminates Heightened Discrimination Standard Under Title VII

Cleaning the Cupboard—Six More Decisions in One Day, and a Largely Harmonious Court - SCOTUS Today

U.S. Supreme Court Holds Majority-Group Plaintiffs Are Not Subject to a Heightened Evidentiary Standard Under Title VII

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Full Alliance Group Launches Qubitera Holdings, to Develop Quant Blockchain and YAHBEE Wallet for Healthcare and Web3
Posted On Monday, July 14, 2025
Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer
Posted On Monday, July 14, 2025
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
Posted On Monday, July 14, 2025
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
Posted On Monday, July 14, 2025
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Posted On Sunday, July 13, 2025
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
Posted On Saturday, July 12, 2025
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted On Friday, July 11, 2025
4DMT Announces New Employment Inducement Grants
Posted On Friday, July 11, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted On Friday, July 11, 2025
Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq
Posted On Friday, July 11, 2025
Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
Posted On Friday, July 11, 2025
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted On Friday, July 11, 2025
Full Alliance Group Obtains FDA MOCRA Registration for HOCl Platform
Posted On Friday, July 11, 2025
Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
Posted On Friday, July 11, 2025
Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025
Posted On Friday, July 11, 2025
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
Posted On Friday, July 11, 2025
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
Posted On Friday, July 11, 2025
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Posted On Friday, July 11, 2025
Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
Posted On Friday, July 11, 2025
NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy
Posted On Thursday, July 10, 2025
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted On Thursday, July 10, 2025
Serina Therapeutics Makes Grant to New Employee Under Inducement Plan
Posted On Thursday, July 10, 2025
Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Posted On Thursday, July 10, 2025
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Posted On Thursday, July 10, 2025
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Posted On Thursday, July 10, 2025

Print